1
|
Dantzler KW, Ma S, Ngotho P, Stone WJR, Tao D, Rijpma S, De Niz M, Nilsson Bark SK, Jore MM, Raaijmakers TK, Early AM, Ubaida-Mohien C, Lemgruber L, Campo JJ, Teng AA, Le TQ, Walker CL, Hermand P, Deterre P, Davies DH, Felgner P, Morlais I, Wirth DF, Neafsey DE, Dinglasan RR, Laufer M, Huttenhower C, Seydel K, Taylor T, Bousema T, Marti M. Naturally acquired immunity against immature Plasmodium falciparum gametocytes. Sci Transl Med 2020; 11:11/495/eaav3963. [PMID: 31167926 DOI: 10.1126/scitranslmed.aav3963] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2018] [Accepted: 04/05/2019] [Indexed: 12/11/2022]
Abstract
The recent decline in global malaria burden has stimulated efforts toward Plasmodium falciparum elimination. Understanding the biology of malaria transmission stages may provide opportunities to reduce or prevent onward transmission to mosquitoes. Immature P. falciparum transmission stages, termed stages I to IV gametocytes, sequester in human bone marrow before release into the circulation as mature stage V gametocytes. This process likely involves interactions between host receptors and potentially immunogenic adhesins on the infected red blood cell (iRBC) surface. Here, we developed a flow cytometry assay to examine immune recognition of live gametocytes of different developmental stages by naturally exposed Malawians. We identified strong antibody recognition of the earliest immature gametocyte-iRBCs (giRBCs) but not mature stage V giRBCs. Candidate surface antigens (n = 30), most of them shared between asexual- and gametocyte-iRBCs, were identified by mass spectrometry and mouse immunizations, as well as correlations between responses by protein microarray and flow cytometry. Naturally acquired responses to a subset of candidate antigens were associated with reduced asexual and gametocyte density, and plasma samples from malaria-infected individuals were able to induce immune clearance of giRBCs in vitro. Infected RBC surface expression of select candidate antigens was validated using specific antibodies, and genetic analysis revealed a subset with minimal variation across strains. Our data demonstrate that humoral immune responses to immature giRBCs and shared iRBC antigens are naturally acquired after malaria exposure. These humoral immune responses may have consequences for malaria transmission potential by clearing developing gametocytes, which could be leveraged for malaria intervention.
Collapse
Affiliation(s)
- Kathleen W Dantzler
- Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, Boston, MA, USA.,Wellcome Centre for Molecular Parasitology, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
| | - Siyuan Ma
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | - Priscilla Ngotho
- Wellcome Centre for Molecular Parasitology, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
| | - Will J R Stone
- Radboud Institute for Health Sciences, Radboud University Medical Center, Netherlands.,Immunology and Infection Department, London School of Hygiene and Tropical Medicine, London, UK
| | - Dingyin Tao
- W. Harry Feinstone Department of Molecular Microbiology and Immunology and the Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.,National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Sanna Rijpma
- Radboud Institute for Health Sciences, Radboud University Medical Center, Netherlands
| | - Mariana De Niz
- Wellcome Centre for Molecular Parasitology, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
| | - Sandra K Nilsson Bark
- Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | - Matthijs M Jore
- Radboud Institute for Health Sciences, Radboud University Medical Center, Netherlands
| | - Tonke K Raaijmakers
- Radboud Institute for Health Sciences, Radboud University Medical Center, Netherlands
| | | | | | - Leandro Lemgruber
- Wellcome Centre for Molecular Parasitology, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
| | | | | | | | | | - Patricia Hermand
- Sorbonne Universités, UPMC Univ Paris 06, INSERM, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), UMR 1135, ERL CNRS 8255, F-75013 Paris, France
| | - Philippe Deterre
- Sorbonne Universités, UPMC Univ Paris 06, INSERM, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), UMR 1135, ERL CNRS 8255, F-75013 Paris, France
| | - D Huw Davies
- Division of Infectious Diseases, Department of Medicine, University of California, Irvine, CA, USA
| | - Phil Felgner
- Division of Infectious Diseases, Department of Medicine, University of California, Irvine, CA, USA
| | - Isabelle Morlais
- UMR MIVEGEC UM1-CNRS 5290-IRD 224, Institut de Recherche pour le Développement, Montpellier Cedex, France
| | - Dyann F Wirth
- Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | | | - Rhoel R Dinglasan
- W. Harry Feinstone Department of Molecular Microbiology and Immunology and the Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.,Emerging Pathogens Institute, Department of Infectious Diseases and Immunology, University of Florida College of Veterinary Medicine, Gainesville, FL, USA
| | - Miriam Laufer
- Division of Malaria Research, Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Curtis Huttenhower
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | - Karl Seydel
- Department of Osteopathic Medical Specialties, College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA.,Blantyre Malaria Project, University of Malawi College of Medicine, Blantyre, Malawi
| | - Terrie Taylor
- Department of Osteopathic Medical Specialties, College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA.,Blantyre Malaria Project, University of Malawi College of Medicine, Blantyre, Malawi
| | - Teun Bousema
- Radboud Institute for Health Sciences, Radboud University Medical Center, Netherlands. .,Immunology and Infection Department, London School of Hygiene and Tropical Medicine, London, UK
| | - Matthias Marti
- Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, Boston, MA, USA. .,Wellcome Centre for Molecular Parasitology, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
| |
Collapse
|
2
|
Baudesson de Chanville C, Chousterman BG, Hamon P, Laviron M, Guillou N, Loyher PL, Meghraoui-Kheddar A, Barthelemy S, Deterre P, Boissonnas A, Combadière C. Sepsis Triggers a Late Expansion of Functionally Impaired Tissue-Vascular Inflammatory Monocytes During Clinical Recovery. Front Immunol 2020; 11:675. [PMID: 32425929 PMCID: PMC7212400 DOI: 10.3389/fimmu.2020.00675] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Accepted: 03/25/2020] [Indexed: 12/20/2022] Open
Abstract
Sepsis is characterized by a systemic inflammation that can cause an immune dysfunction, for which the underlying mechanisms are unclear. We investigated the impact of cecal ligature and puncture (CLP)-mediated polymicrobial sepsis on monocyte (Mo) mobilization and functions. Our results show that CLP led to two consecutive phases of Mo deployment. The first one occurred within the first 3 days after the induction of the peritonitis, while the second phase was of a larger amplitude and extended up to a month after apparent clinical recovery. The latter was associated with the expansion of Mo in the tissue reservoirs (bone marrow and spleen), their release in the blood and their accumulation in the vasculature of peripheral non-lymphoid tissues. It occurred even after antibiotic treatment but relied on inflammatory-dependent pathways and inversely correlated with increased susceptibility and severity to a secondary infection. The intravascular lung Mo displayed limited activation capacity, impaired phagocytic functions and failed to transfer efficient protection against a secondary infection into monocytopenic CCR2-deficient mice. In conclusion, our work unveiled key dysfunctions of intravascular inflammatory Mo during the recovery phase of sepsis and provided new insights to improve patient protection against secondary infections.
Collapse
Affiliation(s)
| | - Benjamin Glenn Chousterman
- Inserm UMRS 1160, Département d'Anesthésie-Réanimation, Hôpitaux Universitaires Lariboisière-Saint-Louis, Paris, France
| | - Pauline Hamon
- Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France
| | - Marie Laviron
- Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France
| | - Noelline Guillou
- Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France
| | - Pierre Louis Loyher
- Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France
| | - Aida Meghraoui-Kheddar
- Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France
| | - Sandrine Barthelemy
- Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France
| | - Philippe Deterre
- Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France
| | - Alexandre Boissonnas
- Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France
| | - Christophe Combadière
- Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France
| |
Collapse
|
3
|
Auvynet C, Baudesson de Chanville C, Hermand P, Dorgham K, Piesse C, Pouchy C, Carlier L, Poupel L, Barthélémy S, Felouzis V, Lacombe C, Sagan S, Chemtob S, Quiniou C, Salomon B, Deterre P, Sennlaub F, Combadière C. ECL1i, d(LGTFLKC), a novel, small peptide that specifically inhibits CCL2-dependent migration. FASEB J 2016; 30:2370-81. [PMID: 26979087 DOI: 10.1096/fj.201500116] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2015] [Accepted: 02/25/2016] [Indexed: 11/11/2022]
Abstract
CC chemokine receptor type 2 (CCR2) is a key molecule in inflammatory diseases and is an obvious drug target for the treatment of inflammation. A number of nonpeptidic, competitive CCR2 antagonists have been developed, but none has yet been approved for clinical use. Our aim was to identify a short peptide that showed allosteric antagonism against human and mouse CCR2. On the basis of sequence analysis and 3-dimensional modeling, we identified an original 7-d-amino acid peptidic CCR2 inhibitor that we have called extracellular loop 1 inverso (ECL1i), d(LGTFLKC). In vitro, ECL1i selectively and potently inhibits CC chemokine ligand type 2 (CCL2)-triggered chemotaxis (IC50, 2 µM) but no other conventional CCL2-associated events. We used the classic competitive CCR2 antagonist, BMS22 {2-[(isopropylaminocarbonyl)amino]-N-[2-[[cis-2-[[4-(methylthio)benzoyl]amino]cyclohexyl]amino]-2-oxoethyl]-5-(trifluoromethyl)benzamide}, as positive control and inhibited CCL2-dependent chemotaxis with an IC50 of 18 nM. As negative control, we used a peptide with the same composition as ECL1i, but in a different sequence, d(FKLTLCG). In vivo, ECL1i (4 mg/kg) interfered with CCR2-positive cell recruitment and attenuated disease progression in experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis. This study establishes ECL1i as the first allosteric inhibitor of CCR2 with functional selectivity. ECL1i is a promising new agent in therapeutic development, and it may, by its selective effect, increase our understanding of CCR2 signaling pathways and functions.-Auvynet, C., Baudesson de Chanville, C., Hermand, P., Dorgham, K., Piesse, C., Pouchy, C., Carlier, L., Poupel, L., Barthélémy, S., Felouzis, V., Lacombe, C., Sagan, S., Salomon, B., Deterre, P., Sennlaub, F., Combadière, C. ECL1i, d(LGTFLKC), a novel, small peptide that specifically inhibits CCL2-dependent migration.
Collapse
Affiliation(s)
- Constance Auvynet
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Camille Baudesson de Chanville
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Patricia Hermand
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Karim Dorgham
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Christophe Piesse
- Sorbonne Universités, UPMC/Univ Paris 06, Institut de Biologie Paris-Seine (IBPS) 3631, CNRS, Service de Synthése Peptidique, Paris, France
| | - Charlotte Pouchy
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Ludovic Carlier
- Sorbonne Universités, UPMC/Univ Paris 06, CNRS, UMR 7203, Laboratoire des Biomolécules, Paris, France
| | - Lucie Poupel
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Sandrine Barthélémy
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Virginie Felouzis
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Claire Lacombe
- Sorbonne Universités, UPMC/Univ Paris 06, CNRS, UMR 7203, Laboratoire des Biomolécules, Paris, France; Ecole Normale Supérieure-Université de Recherche Paris Sciences et Lettres, Département de Chimie, Paris, France; Faculté des Sciences et Technologie, Université Paris Est Créteil-Val de Marne, Créteil, France
| | - Sandrine Sagan
- Sorbonne Universités, UPMC/Univ Paris 06, CNRS, UMR 7203, Laboratoire des Biomolécules, Paris, France
| | | | | | - Benoit Salomon
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Philippe Deterre
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Florian Sennlaub
- Sorbonne Universités, UPMC/ Univ Paris 06, UMRS 968, INSERM, U968, Institut de la Vision, Paris, France; Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, INSERM-Direction des Hôpitaux et de l'Offre de Soins (DHOS), Centre d'Investigation Clinique 503, Paris, France
| | - Christophe Combadière
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France;
| |
Collapse
|
4
|
Felouzis V, Hermand P, de Laissardière GT, Combadière C, Deterre P. Comprehensive analysis of chemokine-induced cAMP-inhibitory responses using a real-time luminescent biosensor. Cell Signal 2015; 28:120-9. [PMID: 26515128 DOI: 10.1016/j.cellsig.2015.10.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2015] [Accepted: 10/23/2015] [Indexed: 01/29/2023]
Abstract
Chemokine receptors are members of the G-protein-coupled receptor (GPCR) family coupled to members of the Gi class, whose primary function is to inhibit the cellular adenylate cyclase. We used a cAMP-related and PKA-based luminescent biosensor (GloSensor™ F-22) to monitor the real-time downstream response of chemokine receptors, especially CX3CR1 and CXCR4, after activation with their cognate ligands CX3CL1 and CXCL12. We found that the amplitudes and kinetic profiles of the chemokine responses were conserved in various cell types and were independent of the nature and concentration of the molecules used for cAMP prestimulation, including either the adenylate cyclase activator forskolin or ligands mediating Gs-mediated responses like prostaglandin E2 or beta-adrenergic agonist. We conclude that the cAMP chemokine response is robustly conserved in various inflammatory conditions. Moreover, the cAMP-related luminescent biosensor appears as a valuable tool to analyze the details of Gi-mediated cAMP-inhibitory cellular responses, even in native conditions and could help to decipher their precise role in cell function.
Collapse
Affiliation(s)
- Virginia Felouzis
- Sorbonne Universités, UPMC Université Paris 06, Inserm U 1135, CNRS ERL 8255, Centre d'Immunologie et des Maladies Infectieuses, 91 Boulevard de l'Hôpital, F-75013 Paris, France
| | - Patricia Hermand
- Sorbonne Universités, UPMC Université Paris 06, Inserm U 1135, CNRS ERL 8255, Centre d'Immunologie et des Maladies Infectieuses, 91 Boulevard de l'Hôpital, F-75013 Paris, France
| | - Guy Trambly de Laissardière
- Université de Cergy-Pontoise, CNRS, UMR 8089, Laboratoire de Physique Théorique et Modélisation, 2 Avenue A. Chauvin, F-95302 Cergy-Pontoise, France
| | - Christophe Combadière
- Sorbonne Universités, UPMC Université Paris 06, Inserm U 1135, CNRS ERL 8255, Centre d'Immunologie et des Maladies Infectieuses, 91 Boulevard de l'Hôpital, F-75013 Paris, France
| | - Philippe Deterre
- Sorbonne Universités, UPMC Université Paris 06, Inserm U 1135, CNRS ERL 8255, Centre d'Immunologie et des Maladies Infectieuses, 91 Boulevard de l'Hôpital, F-75013 Paris, France.
| |
Collapse
|
5
|
Chousterman BG, Boissonnas A, Poupel L, Baudesson de Chanville C, Adam J, Tabibzadeh N, Licata F, Lukaszewicz AC, Lombès A, Deterre P, Payen D, Combadière C. Ly6Chigh Monocytes Protect against Kidney Damage during Sepsis via a CX3CR1-Dependent Adhesion Mechanism. J Am Soc Nephrol 2015; 27:792-803. [PMID: 26160897 DOI: 10.1681/asn.2015010009] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2015] [Accepted: 05/20/2015] [Indexed: 12/24/2022] Open
Abstract
Monocytes have a crucial role in both proinflammatory and anti-inflammatory phenomena occurring during sepsis. Monocyte recruitment and activation are orchestrated by the chemokine receptors CX3CR1 and CCR2 and their cognate ligands. However, little is known about the roles of these cells and chemokines during the acute phase of inflammation in sepsis. Using intravital microscopy in a murine model of polymicrobial sepsis, we showed that inflammatory Ly6C(high) monocytes infiltrated kidneys, exhibited altered motility, and adhered strongly to the renal vascular wall in a chemokine receptor CX3CR1-dependent manner. Adoptive transfer of Cx3cr1-proficient monocyte-enriched bone marrow cells into septic Cx3cr1-depleted mice prevented kidney damage and promoted mouse survival. Modulation of CX3CR1 activation in septic mice controlled monocyte adhesion, regulated proinflammatory and anti-inflammatory cytokine expression, and was associated with the extent of kidney lesions such that the number of lesions decreased when CX3CR1 activity increased. Consistent with these results, the pro-adhesive I249 CX3CR1 allele in humans was associated with a lower incidence of AKI in patients with sepsis. These data show that inflammatory monocytes have a protective effect during sepsis via a CX3CR1-dependent adhesion mechanism. This receptor might be a new therapeutic target for kidney injury during sepsis.
Collapse
Affiliation(s)
- Benjamin G Chousterman
- Sorbonne Universités, Université Pierre et Marie Curie (UPMC), University of Paris 06, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM), U1135, Paris, France; Centre National de la Recherche Scientifique (CNRS), Paris, France; Département d'Anesthésie-Réanimation-Service d'Aide Médicale Urgente (SMUR), Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Alexandre Boissonnas
- Sorbonne Universités, Université Pierre et Marie Curie (UPMC), University of Paris 06, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM), U1135, Paris, France; Centre National de la Recherche Scientifique (CNRS), Paris, France;
| | - Lucie Poupel
- Sorbonne Universités, Université Pierre et Marie Curie (UPMC), University of Paris 06, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM), U1135, Paris, France; Centre National de la Recherche Scientifique (CNRS), Paris, France
| | - Camille Baudesson de Chanville
- Sorbonne Universités, Université Pierre et Marie Curie (UPMC), University of Paris 06, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM), U1135, Paris, France; Centre National de la Recherche Scientifique (CNRS), Paris, France
| | - Julien Adam
- Institut Gustave-Roussy, Université Paris-Sud Villejuif, France
| | - Nahid Tabibzadeh
- Sorbonne Universités, Université Pierre et Marie Curie (UPMC), University of Paris 06, Paris, France; Service des Explorations Fonctionnelles and Institut National de la Santé et de la Recherche Médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Tenon, Paris, France; and
| | - Fabrice Licata
- Sorbonne Universités, Université Pierre et Marie Curie (UPMC), University of Paris 06, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM), U1135, Paris, France; Centre National de la Recherche Scientifique (CNRS), Paris, France
| | - Anne-Claire Lukaszewicz
- Département d'Anesthésie-Réanimation-Service d'Aide Médicale Urgente (SMUR), Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France; INSERM, U1160, Paris, France
| | - Amélie Lombès
- Sorbonne Universités, Université Pierre et Marie Curie (UPMC), University of Paris 06, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM), U1135, Paris, France; Centre National de la Recherche Scientifique (CNRS), Paris, France
| | - Philippe Deterre
- Sorbonne Universités, Université Pierre et Marie Curie (UPMC), University of Paris 06, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM), U1135, Paris, France; Centre National de la Recherche Scientifique (CNRS), Paris, France
| | - Didier Payen
- Département d'Anesthésie-Réanimation-Service d'Aide Médicale Urgente (SMUR), Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France; INSERM, U1160, Paris, France
| | - Christophe Combadière
- Sorbonne Universités, Université Pierre et Marie Curie (UPMC), University of Paris 06, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM), U1135, Paris, France; Centre National de la Recherche Scientifique (CNRS), Paris, France;
| |
Collapse
|
6
|
Ostuni MA, Guellec J, Hermand P, Durand P, Combadière C, Pincet F, Deterre P. CX3CL1, a chemokine finely tuned to adhesion: critical roles of the stalk glycosylation and the membrane domain. Biol Open 2014; 3:1173-82. [PMID: 25395671 PMCID: PMC4265755 DOI: 10.1242/bio.20149845] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
The multi-domain CX3CL1 transmembrane chemokine triggers leukocyte adherence without rolling and migration by presenting its chemokine domain (CD) to its receptor CX3CR1. Through the combination of functional adhesion assays with structural analysis using FRAP, we investigated the functional role of the other domains of CX3CL1, i.e., its mucin stalk, transmembrane domain, and cytosolic domain. Our results indicate that the CX3CL1 molecular structure is finely adapted to capture CX3CR1 in circulating cells and that each domain has a specific purpose: the mucin stalk is stiffened by its high glycosylation to present the CD away from the membrane, the transmembrane domain generates the permanent aggregation of an adequate amount of monomers to guarantee adhesion and prevent rolling, and the cytosolic domain ensures adhesive robustness by interacting with the cytoskeleton. We propose a model in which quasi-immobile CX3CL1 bundles are organized to quickly generate adhesive patches with sufficiently high strength to capture CX3CR1+ leukocytes but with sufficiently low strength to allow their patrolling behavior.
Collapse
Affiliation(s)
- Mariano A Ostuni
- INSERM, U 1135, Centre d'Immunologie et des Maladies Infectieuses, F-75013, Paris, France Sorbonne Universités, UPMC Université Paris 06, UMRS CR7, Centre d'Immunologie et des Maladies Infectieuses, F-75013, Paris, France CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses, F-75013, Paris, France Present address: INSERM, U 1134, Biologie Intégrée du Globule Rouge; Université Paris Diderot; Institut National de la Transfusion Sanguine, 6 rue Alexandre Cabanel, 75015, Paris, France
| | - Julie Guellec
- INSERM, U 1135, Centre d'Immunologie et des Maladies Infectieuses, F-75013, Paris, France Sorbonne Universités, UPMC Université Paris 06, UMRS CR7, Centre d'Immunologie et des Maladies Infectieuses, F-75013, Paris, France CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses, F-75013, Paris, France
| | - Patricia Hermand
- INSERM, U 1135, Centre d'Immunologie et des Maladies Infectieuses, F-75013, Paris, France Sorbonne Universités, UPMC Université Paris 06, UMRS CR7, Centre d'Immunologie et des Maladies Infectieuses, F-75013, Paris, France CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses, F-75013, Paris, France
| | - Pauline Durand
- Sorbonne Universités, UPMC Université Paris 06, UMR 94550 ENS Laboratoire de Physique Statistique, F-75005, Paris, France
| | - Christophe Combadière
- INSERM, U 1135, Centre d'Immunologie et des Maladies Infectieuses, F-75013, Paris, France Sorbonne Universités, UPMC Université Paris 06, UMRS CR7, Centre d'Immunologie et des Maladies Infectieuses, F-75013, Paris, France CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses, F-75013, Paris, France
| | - Frédéric Pincet
- Sorbonne Universités, UPMC Université Paris 06, UMR 94550 ENS Laboratoire de Physique Statistique, F-75005, Paris, France
| | - Philippe Deterre
- INSERM, U 1135, Centre d'Immunologie et des Maladies Infectieuses, F-75013, Paris, France Sorbonne Universités, UPMC Université Paris 06, UMRS CR7, Centre d'Immunologie et des Maladies Infectieuses, F-75013, Paris, France CNRS, ERL 8255, Centre d'Immunologie et des Maladies Infectieuses, F-75013, Paris, France
| |
Collapse
|
7
|
Jacquelin S, Licata F, Dorgham K, Hermand P, Poupel L, Guyon E, Deterre P, Hume DA, Combadière C, Boissonnas A. CX3CR1 reduces Ly6Chigh-monocyte motility within and release from the bone marrow after chemotherapy in mice. Blood 2013; 122:674-83. [PMID: 23775714 DOI: 10.1182/blood-2013-01-480749] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
The chemokine receptor CCR2 controls the release of Ly6C(high) monocytes from the bone marrow and their recruitment to sites of inflammation. A second chemokine receptor, CX3CR1, is differentially expressed on monocyte subsets. We examined the role of CX3CR1 in monocyte trafficking during the recovery phase after cyclophosphamide (CP)-induced myeloablation and observed that, in the absence of CCR2, Ly6C(high) monocytes accumulated in the bone marrow and peripheral reconstitution was severely impaired compared with wild-type (WT) mice. In contrast, in the absence of CX3CR1, Ly6C(high) monocytes accumulated less rapidly in the marrow but recovered faster in the blood and were more recruited into the spleen, suggesting an opposite action between CCR2 and CX3CR1 in myelorestoration. During the recovery phase, marrow medullar monocytes displayed lower CX3CR1 expression and reduced their adherence to coated CX3CL1. Intravital imaging of the bone marrow showed that CP treatment impacts monocyte trafficking between the parenchyma and the vasculature. Medullar monocytes in CX3CR1(-/-) mice and mice treated with a specific antagonist of CX3CR1 displayed increased mean velocity and displacement and a reduced arrest coefficient compared with WT mice. This study indicates that CX3CR1 reduces the motility of Ly6C(high) monocytes in the bone marrow and thereby controls their release.
Collapse
Affiliation(s)
- Sébastien Jacquelin
- INSERM UMR S945, Immunité et Infection, CHU Pitié-Salpêtrière, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Poupel L, Boissonnas A, Hermand P, Dorgham K, Guyon E, Auvynet C, Charles FS, Lesnik P, Deterre P, Combadiere C. Pharmacological inhibition of the chemokine receptor, CX3CR1, reduces atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2013; 33:2297-305. [PMID: 23887641 DOI: 10.1161/atvbaha.112.300930] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Alterations of the chemokine receptor CX3CR1 gene were associated with a reduced risk of myocardial infarction in human and limited atherosclerosis in mice. In this study, we addressed whether CX3CR1 antagonists are potential therapeutic tools to limit acute and chronic inflammatory processes in atherosclerosis. APPROACH AND RESULTS Treatment with F1, an amino terminus-modified CX3CR1 ligand endowed with CX3CR1 antagonist activity, reduced the extent of atherosclerotic lesions in both Apoe(-/-) and Ldlr(-/-) proatherogenic mouse models. Macrophage accumulation in the aortic sinus was reduced in F1-treated Apoe(-/-) mice but the macrophage density of the lesions was similar in F1-treated and control mice. Both in vitro and in vivo F1 treatment reduced CX3CR1-dependent inflammatory monocyte adhesion, potentially limiting their recruitment. In addition, F1-treated Apoe(-/-) mice displayed reduced numbers of blood inflammatory monocytes, whereas resident monocyte numbers remained unchanged. Both in vitro and in vivo F1 treatment reduced CX3CR1-dependent inflammatory monocyte survival. Finally, F1 treatment of Apoe(-/-) mice with advanced atherosclerosis led to smaller lesions than untreated mice but without reverting to the initial phenotype. CONCLUSIONS The CX3CR1 antagonist F1 is a potent inhibitor of the progression of atherosclerotic lesions by means of its selective impact on inflammatory monocyte functions. Controlling monocyte trafficking and survival may be an alternative or complementary therapy to lipid-lowering drugs classically used in the treatment of atherosclerosis.
Collapse
Affiliation(s)
- Lucie Poupel
- From UMR_S 945, Laboratoire "Immunité et Infection," Inserm Paris, France and Université Pierre et Marie Curie- (UPMC) Paris 6, Paris, France (L.P., A.B., P.H., K.D., E.G., C.A., P.D., C.C.); UMR_S 939 P.LUMR_S 939, Laboratoire "Dyslipidémies, Inflammation et Athérosclérose," Paris, France (F.S.C., P.L.); and AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d'Immunologie, Paris, France (C.C.)
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Deterre P. In search of science, in search of meaning. EPJ Web of Conferences 2012. [DOI: 10.1051/epjconf/20123401004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
10
|
Darbandi-Tehrani K, Hermand P, Carvalho S, Dorgham K, Couvineau A, Lacapère JJ, Combadière C, Deterre P. Subtle conformational changes between CX3CR1 genetic variants as revealed by resonance energy transfer assays. FASEB J 2010; 24:4585-98. [PMID: 20667981 DOI: 10.1096/fj.10-156612] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The chemokine CX3CL1 is expressed as a membrane protein that forms a potent adhesive pair with its unique receptor CX3CR1. This receptor has 3 natural variants, V249-T280 (VT), I249-T280 (IT), and I249-M280 (IM), whose relative frequencies are significantly associated with the incidence of various inflammatory diseases. To assess the adhesive potency of CX3CR1 and the molecular diversity of its variants, we assayed their clustering status and their possible structural differences by fluorescence/bioluminescence resonance energy transfer (FRET or BRET) techniques. FRET assays by flow cytometry showed that the CX3CR1 variants cluster, in comparison with appropriate controls. BRET assays showed low nonspecific signals for VT and IT variants and high specific signals for IM, and thus pointed out a structural difference in this variant. We used molecular modeling to show how natural point mutations of CX3CR1 affect the packing of the 6th and 7th helices of this G-protein coupled receptor. Moreover, we found that the BRET technique is sensitive enough to detect these tiny changes. Consistently with our previous finding that CX3CL1 aggregates, our data here indicate that CX3CR1 clustering may contribute to the adhesiveness of the CX3CL1-CX3CR1 pair and may thus represent a new target for anti-inflammatory therapies.
Collapse
|
11
|
Jamieson WL, Dorgham K, Deterre P, Fatatis A. Abstract 2361: Fractalkine and CX3CR1 are involved in the early stages of skeletal metastasis. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-2361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
It is estimated that eighty percent of breast cancer (BCa) and ninety percent of prostate cancer (PCa) patients develop late-stage skeletal metastases. Metastatic disease is the major cause of death in these patients and only palliative treatments for clinically established skeletal metastases are available. In order to develop effective preventive and curative therapies, it is essential that mechanisms involved in cancer cell bone colonization are fully understood. Our previous in vitro experiments have shown that the chemokine fractalkine (FKN, CX3CL1) and its receptor, CX3CR1, mediate adhesion of PCa cells to bone marrow endothelial cells as well as their migration toward osteoblasts. We have also shown that CX3CR1 is highly expressed in BCa and PCa cell lines as well as ex vivo prostate and mammary human cancer tissues, whereas FKN is expressed by stromal cells of the bone marrow. Therefore, we hypothesize that FKN and CX3CR1 are involved in the arrival and arrest of cancer cells to the bone during the metastatic process. To test our hypothesis, we employed a mouse model of metastasis in which fluorescent human cancer cells are inoculated in the left cardiac ventricle. Using a histology-stereomicroscopy combination approach, we detect single cancer cells in the bone microenvironment as early as 24 hours after their delivery into the blood stream. Analyses at later time-points also reveal the progression of small cancer foci into macroscopic metastases. Inoculation of PCa or BCa cells in FKN-null mice shows a significant decrease in the number of cancer cells disseminated to the skeleton by hematogenous route. In parallel experiments, exogenous over-expression of CX3CR1 in BCa cells increases their arrival to bone. On the other hand, upon expression of a CX3CR1 functional mutant - unable to mediate adhesion to FKN - the dissemination of BCa cells to the skeleton is significantly impaired. Finally, we used a newly engineered inhibitor of CX3CR1 to counteract skeletal metastases in vivo.
In conclusion, our data present strong evidence that the FKN/CX3CR1 pair is involved in the early stages of prostate and breast cancer bone metastasis. Thus, altering the interactions between FKN and its receptor represents an attractive therapeutic approach for the prevention of skeletal metastases from prostate and breast cancer.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2361.
Collapse
Affiliation(s)
| | - Karim Dorgham
- 2INSERM and Université Pierre et Marie Curie, Paris, France
| | | | | |
Collapse
|
12
|
Barbaux S, Poirier O, Pincet F, Hermand P, Tiret L, Deterre P. The adhesion mediated by the P-selectin P-selectin glycoprotein ligand-1 (PSGL-1) couple is stronger for shorter PSGL-1 variants. J Leukoc Biol 2010; 87:727-34. [DOI: 10.1189/jlb.0609408] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
|
13
|
Dorgham K, Ghadiri A, Hermand P, Rodero M, Poupel L, Iga M, Hartley O, Gorochov G, Combadière C, Deterre P. An engineered CX3CR1 antagonist endowed with anti-inflammatory activity. J Leukoc Biol 2009; 86:903-11. [PMID: 19571253 DOI: 10.1189/jlb.0308158] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Chemokines are mainly involved in the recruitment of leukocytes into tissues, a key feature of inflammation. Through its unique receptor CX3CR1, the chemokine CX3CL1 participates in diverse inflammatory processes including arterial atherosclerosis and cerebral or renal inflammation. Using a phage display strategy, we engineered a hCX3CL1 analog (named F1) with a modified N terminus. F1 bound specifically to cells expressing hCX3CR1 and had a K(d) value close to that of native CX3CL1. F1 was not a signaling molecule and did not induce chemotaxis, calcium flux, or CX3CR1 internalization. However, it potently inhibited the CX3CL1-induced calcium flux and chemotaxis in CX3CR1-expressing primary cells of human and murine origin with an IC(50) of 5-50 nM. It also efficiently inhibited the cell adhesion mediated by the CX3CL1-CX3CR1 axis. Finally, in a noninfectious murine model of peritonitis, F1 strongly inhibited macrophage accumulation. These data reveal a prototype molecule that is the first bona fide antagonist of hCX3CR1. This molecule could be used as a lead compound for the development of a novel class of anti-inflammatory substances that act by inhibiting CX3CR1.
Collapse
Affiliation(s)
- Karim Dorgham
- INSERM UMR-S 945, UPMC Paris 6, Faculté de Médecine Pitié-Salpêtrière, Laboratoire Immunitét Infection, 75013 Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Chabre M, Deterre P, Antonny B. The apparent cooperativity of some GPCRs does not necessarily imply dimerization. Trends Pharmacol Sci 2009; 30:182-7. [DOI: 10.1016/j.tips.2009.01.003] [Citation(s) in RCA: 87] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2008] [Revised: 01/26/2009] [Accepted: 01/27/2009] [Indexed: 11/17/2022]
|
15
|
Rodero M, Marie Y, Coudert M, Blondet E, Mokhtari K, Rousseau A, Raoul W, Carpentier C, Sennlaub F, Deterre P, Delattre JY, Debré P, Sanson M, Combadière C. Polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma. J Clin Oncol 2008; 26:5957-64. [PMID: 19001328 DOI: 10.1200/jco.2008.17.2833] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
PURPOSE Few reliable prognostic molecular markers have been characterized for glioblastoma multiforme (GBM), considered the deadliest of human cancers. We hypothesized that genetic polymorphisms in chemokines and their receptors, which together control microglial cell mobilization, may influence survival. METHODS Distributions of one polymorphism of the chemokine CCL2 (-2518A<G) and two polymorphisms of the chemokine receptor CX3CR1 (termed V249I and T280M) were determined in a prospective series of 230 patients with GBM and correlated with overall survival. The replication study used data from a retrospective series of 106 additional patients with GBM. The extent of microglial cell infiltration was assessed by immunochemistry in 102 tumor specimens. RESULTS Survival analysis showed that the common CX3CR1-I249 allele was an independent favorable prognostic factor in both groups, prospective and retrospective, with hazard ratios of 0.619 (95% CI, 0.451 to 0.850; P = .0031) and 0.354 (95% CI, 0.217 to 0.580; P < .0001), respectively. This beneficial effect was observed only in patients who underwent surgery. Patients with only this CX3CR1-I249 allele had a substantially longer mean survival (23.5 v 14.1 months; P < .0001). The CCL2-2518G allele was not associated with patient survival. Immunohistochemical analysis of primary tumor biopsies showed that the common CX3CR1 variant allele was associated with reduced microglial cell infiltration. CONCLUSION The common CX3CR1 allelic variant was associated with increased GBM survival and with reduced tumor infiltration by microglia. The CX3CR1 polymorphism does not seem to be a risk factor for GBM but may prove useful in predicting survival.
Collapse
Affiliation(s)
- Mathieu Rodero
- Laboratoire d'Immunologie Cellulaire, L'Institut National de Santé et de Recherche Médicale U543, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Hermand P, Pincet F, Carvalho S, Ansanay H, Trinquet E, Daoudi M, Combadière C, Deterre P. Functional adhesiveness of the CX3CL1 chemokine requires its aggregation. Role of the transmembrane domain. J Biol Chem 2008; 283:30225-34. [PMID: 18725411 DOI: 10.1074/jbc.m802638200] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
In its native form, the chemokine CX3CL1 is a firmly adhesive molecule promoting leukocyte adhesion and migration and hence involved, along with its unique receptor CX3CR1, in various inflammatory processes. Here we investigated the role of molecular aggregation in the CX3CL1 adhesiveness. Assays of bioluminescence resonance energy transfer (BRET) and homogeneous time-resolved fluorescence (HTRF) in transfected cell lines and in primary cells showed specific signals indicative of CX3CL1 clustering. Truncation experiments showed that the transmembrane domain played a central role in this aggregation. A chimera with mutations of the 12 central transmembrane domain residues had significantly reduced BRET signals and characteristics of a non-clustering molecule. This mutant was weakly adhesive according to flow and dual pipette adhesion assays and was less glycosylated than CX3CL1, although, as we demonstrated, loss of glycosylation did not affect the CX3CL1 adhesive potency. We postulate that cell surfaces express CX3CL1 as a constitutive oligomer and that this oligomerization is essential for its adhesive potency. Inhibition of CX3CL1 self-assembly could limit the recruitment of CX3CR1-positive cells and may be a new pathway for anti-inflammatory therapies.
Collapse
Affiliation(s)
- Patricia Hermand
- Laboratoire d'Immunologie Cellulaire, INSERM UMR-S 543, Université Pierre et Marie Curie-Paris 06, 91 boulevard de l'Hôpital, 75013 Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Combadière C, Feumi C, Raoul W, Keller N, Rodéro M, Pézard A, Lavalette S, Houssier M, Jonet L, Picard E, Debré P, Sirinyan M, Deterre P, Ferroukhi T, Cohen SY, Chauvaud D, Jeanny JC, Chemtob S, Behar-Cohen F, Sennlaub F. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J Clin Invest 2007; 117:2920-8. [PMID: 17909628 PMCID: PMC1994614 DOI: 10.1172/jci31692] [Citation(s) in RCA: 435] [Impact Index Per Article: 25.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2007] [Accepted: 06/26/2007] [Indexed: 11/17/2022] Open
Abstract
The role of retinal microglial cells (MCs) in age-related macular degeneration (AMD) is unclear. Here we demonstrated that all retinal MCs express CX3C chemokine receptor 1 (CX3CR1) and that homozygosity for the CX3CR1 M280 allele, which is associated with impaired cell migration, increases the risk of AMD. In humans with AMD, MCs accumulated in the subretinal space at sites of retinal degeneration and choroidal neovascularization (CNV). In CX3CR1-deficient mice, MCs accumulated subretinally with age and albino background and after laser impact preceding retinal degeneration. Raising the albino mice in the dark prevented both events. The appearance of lipid-bloated subretinal MCs was drusen-like on funduscopy of senescent mice, and CX3CR1-dependent MC accumulation was associated with an exacerbation of experimental CNV. These results show that CX3CR1-dependent accumulation of subretinal MCs evokes cardinal features of AMD. These findings reveal what we believe to be a novel pathogenic process with important implications for the development of new therapies for AMD.
Collapse
Affiliation(s)
- Christophe Combadière
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - Charles Feumi
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - William Raoul
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - Nicole Keller
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - Mathieu Rodéro
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - Adeline Pézard
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - Sophie Lavalette
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - Marianne Houssier
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - Laurent Jonet
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - Emilie Picard
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - Patrice Debré
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - Mirna Sirinyan
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - Philippe Deterre
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - Tania Ferroukhi
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - Salomon-Yves Cohen
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - Dominique Chauvaud
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - Jean-Claude Jeanny
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - Sylvain Chemtob
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - Francine Behar-Cohen
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| | - Florian Sennlaub
- INSERM U543, Laboratoire d’Immunologie Cellulaire, Paris, France.
Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d’Immunologie, Paris, France.
INSERM U872, Paris, France.
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Laboratoire d’informatique de Paris 6, Paris, France.
Université Paris Descartes, UMR S 872, Paris, France.
Department of Pediatrics, Ophthalmology and Pharmacology, Research Center, Hôpital Ste Justine, Montréal, Québec, Canada.
Centre d’Angiographie et de Laser, Paris, France.
AP-HP, Hôtel Dieu, Service d’Ophtalmologie, Centre de Recherche Ophtalmologique, Paris, France
| |
Collapse
|
18
|
Abstract
The immune system relies on the motility on various cell types that roam the host through the blood, the peripheral tissues and the lymphoid organs, looking for pathogens. Along their maturation and/or activation, the cell migratory capacities change in order to allow them to leave organs where they have been produced such as thymus and bone marrow, to locate in strategic sites to sense surrounding microbes, to meet and interact with other cells, and finally to access peripheral tissues and organs to eradicate the pathogens. This cell traffic is a highly organized process that involves numerous protein families such as adhesion molecules, proteases and chemotactic factors. Among the latter, chemokines are in the front line. We will here summarize the recent findings stressing out their physiopathological relevance and will describe thereafter their possible therapeutic use.
Collapse
Affiliation(s)
- Béhazine Combadière
- Laboratoire d'immunologie cellulaire, Inserm U543, Université Pierre-et-Marie Curie, Faculté de Médecine Pitié-Salpêtrière, 91, boulevard de l'Hôpital, 75634 Paris Cedex 13, France
| | | | | |
Collapse
|
19
|
Capoulade-Métay C, Ayouba A, Kfutwah A, Lole K, Pêtres S, Dudoit Y, Deterre P, Menu E, Barré-Sinoussi F, Debré P, Theodorou I. A natural CCL5/RANTES variant antagonist for CCR1 and CCR3. Immunogenetics 2006; 58:533-41. [PMID: 16791620 DOI: 10.1007/s00251-006-0133-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2006] [Accepted: 05/17/2006] [Indexed: 12/29/2022]
Abstract
The N-terminal domain of the chemokine CCL5/regulated upon activation normal T cell expressed and secreted (RANTES) has been shown to be critical for its biological activity on leukocytes. Several N-terminus-modified CCL5/RANTES derivatives, such as N-Terminal truncated CCL5/RANTES, Met-RANTES, and amino-oxypentane (AOP)-RANTES exhibited antagonist or partial agonist functions when investigated on the properties of their receptors CCR1, CCR3, and CCR5. Studying 95 African samples from Cameroon, we found a naturally occurring variant of CCL5/RANTES containing a missense mutation located in the first amino acid of the secreted form (S24F). S24F binds CCR1, CCR3, and CCR5 and triggers receptor down-modulation comparable to CCL5/RANTES. Moreover, in CCR5 positive cells, S24F elicits cellular calcium mobilization equivalent to that obtained with CCL5/RANTES. By contrast, S24F does not provoke any response in CCR1 and CCR3 positive cells. As CCL5/RANTES is able to attract different subtypes of leukocytes into inflamed tissue and intervenes in a wide range of allergic and autoimmune diseases, the discovery of this natural N-terminus-modified CCL5/RANTES analogue exhibiting differential effects on CCL5/RANTES receptors, opens up additional perspectives for therapeutic intervention.
Collapse
|
20
|
Lavergne E, Labreuche J, Daoudi M, Debré P, Cambien F, Deterre P, Amarenco P, Combadière C. Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. Arterioscler Thromb Vasc Biol 2005; 25:847-53. [PMID: 15681302 DOI: 10.1161/01.atv.0000157150.23641.36] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE We investigated the role of monocyte-recruiting chemokines in cerebrovascular diseases among the subjects of the GENIC case-control study of brain infarction (BI). METHODS AND RESULTS Of the genotypes tested, only homozygosity for the rare CX3CR1 alleles was more frequent in cases than in controls: the I249 and M280 alleles were associated with an increased risk of BI (OR, 1.66 and OR, 2.62 with P<0.05, respectively). This effect was independent of other established risk factors and uncorrelated with disease severity. The study confirmed previous reports of a dominant protective association between CX3CR1-I249 allele and the risk of cardiovascular history. The risk of BI associated with homozygosity for the rare CX3CR1 alleles was enhanced in patients with no previous cardiovascular events. Ex vivo studies showed that the number of monocytes adhering to immobilized CX3CL1, the CX3CR1 ligand, increased proportionally to the number of CX3CR1 mutated alleles carried by the individual. CONCLUSIONS The rare CX3CR1 alleles were associated with an increased risk of BI and with reduced frequency of cardiovascular history. We propose that the extra adhesion of monocytes observed in individuals carrying rare alleles of CX3CR1 may favor mechanisms leading to stroke.
Collapse
Affiliation(s)
- Elise Lavergne
- Laboratoire d'Immunologie Cellulaire, INSERM U543, Hôpital Pitié-Salpêtrière, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Spano JP, Andre F, Morat L, Sabatier L, Besse B, Combadiere C, Deterre P, Martin A, Azorin J, Valeyre D, Khayat D, Le Chevalier T, Soria JC. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol 2004; 15:613-7. [PMID: 15033669 DOI: 10.1093/annonc/mdh136] [Citation(s) in RCA: 179] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The expression of CXCR4 has been implicated in metastatic dissemination in different models of breast cancer and melanoma. In the present study, we evaluated CXCR4 expression in non-small-cell lung cancer (NSCLC) and the relationship between CXCR4 expression and the prognosis of stage I disease. PATIENTS AND METHODS Using immunohistochemical analysis, we retrospectively analyzed CXCR4 expression in specimens from 61 patients with completely resected pathologically confirmed stage I NSCLC for whom clinical follow-up data were available. RESULTS In the present study, we have shown that: CXCR4 is expressed by tumor cells in stage I NSCLC; CXCR4 is located in the nucleus and/or in the cytoplasm of tumor cells; strong nuclear staining was observed in 17 cases (29.8%); patients whose tumors had CXCR4-positive nuclear staining had a significantly longer duration of survival than patients whose tumors had no nuclear expression (P = 0.039, log-rank test). Interestingly, the 5-year metastasis rates were 23.5% and 34.1% in patients with CXCR4-positive and CXCR4-negative nuclear expression, respectively (P = 0.2). CONCLUSION Strong CXCR4-positive nuclear staining was associated with a significantly better outcome in early-stage NSCLC. The mechanisms underlying this clinically and biologically important finding need to be further explored.
Collapse
Affiliation(s)
- J-P Spano
- SOMPS, Pitié Salpetrière Hospital, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Daoudi M, Lavergne E, Garin A, Tarantino N, Debré P, Pincet F, Combadière C, Deterre P. Enhanced adhesive capacities of the naturally occurring Ile249-Met280 variant of the chemokine receptor CX3CR1. J Biol Chem 2004; 279:19649-57. [PMID: 14990582 DOI: 10.1074/jbc.m313457200] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
It was recently shown that individuals carrying the naturally occurring mutant CX3CR1-Ile(249)-Met(280) (hereafter called CX3CR1-IM) have a lower risk of cardiovascular disease than individuals homozygous for the wild-type CX3CR1-Val(249)-Thr(280) (CX3CR1-VT). We report here that peripheral blood mononuclear cells (PBMC) from individuals with the CX3CR1-IM haplotype adhered more potently to membrane-bound CX3CL1 than did PBMC from homozygous CX3CR1-VT donors. Similar excess adhesion was observed with CX3CR1-IM-transfected human embryonic kidney (HEK) cell lines tested with two different methods: the parallel plate laminar flow chamber and the dual pipette aspiration technique. Suppression of the extra adhesion in the presence of pertussis toxin indicates that G-protein mediated the underlying transduction pathway, in contrast to the G-protein-independent adhesion previously described for CX3CR1-VT. Surprisingly, HEK and PBMC that expressed CX3CR1-IM and -VT were indistinguishable when tested with the soluble form of CX3CL1 for chemotaxis, calcium release, and binding capacity. In conclusion, only the membrane-anchored form of CX3CL1 functionally discriminated between these two allelic isoforms of CX3CR1. These results suggest that each form of this ligand may lead to a different signaling pathway. The extra adhesion of CX3CR1-IM may be related to immune defenses and to atherogenesis, both of which depend substantially on adhesive intercellular events.
Collapse
Affiliation(s)
- Mehdi Daoudi
- Laboratoire d'Immunologie Cellulaire, INSERM U543, Faculté de Médecine Pitié-Salpêtrière, 91 Boulevard de l'Hôpital, 75013 Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Lacapère JJ, Boulla G, Lund FE, Primack J, Oppenheimer N, Schuber F, Deterre P. Fluorometric studies of ligand-induced conformational changes of CD38. Biochim Biophys Acta 2003; 1652:17-26. [PMID: 14580993 DOI: 10.1016/j.bbapap.2003.07.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The lymphoid surface antigen CD38 is a NAD(+)-glycohydrolase that also catalyzes the transformation of NAD(+) into cyclic ADP-ribose, a calcium mobilizing second messenger. In addition, ligation of CD38 by antibodies triggers signaling in lymphoid cells. Since the cytoplasmic tail of CD38 is dispensable for this latter property, we have previously proposed that CD38-mediated receptor signal transduction might be regulated by its conformational state. We have now examined the molecular changes of this protein during its interaction with NAD(+) by measuring the intrinsic fluorescence of CD38. We have shown that addition of the substrate produced a dramatic decrease in the fluorescence of the catalytically active recombinant soluble ectodomain of murine CD38. Analysis of this event revealed that the catalytic cycle involves a state of the enzyme that is characterized by a low fluorescence which, upon substrate turnover, reverts to the initial high intrinsic fluorescence level. In contrast, non-hydrolyzable substrates trap CD38 in its altered low fluorescence state. Studies with the hydrophilic quencher potassium iodide revealed that the tryptophan residues that are mainly involved in the observed changes in fluorescence, are remote from the active site. Similar data were also obtained with human CD38, indicating that studies of intrinsic fluorescence will be useful in monitoring the transconformation of CD38 from different species. Together, these data demonstrate that CD38 undergoes a reversible conformational change after substrate binding, and suggest a mechanism by which this change could alter interactions with different cell-surface partners.
Collapse
Affiliation(s)
- Jean-Jacques Lacapère
- INSERM U410, Faculté de Médecine Xavier Bichat, 16 rue Henri Huchard, 75018 Paris, France
| | | | | | | | | | | | | |
Collapse
|
24
|
Garin A, Tarantino N, Faure S, Daoudi M, Lécureuil C, Bourdais A, Debré P, Deterre P, Combadiere C. Two Novel Fully Functional Isoforms of CX3CR1 Are Potent HIV Coreceptors. J Immunol 2003; 171:5305-12. [PMID: 14607932 DOI: 10.4049/jimmunol.171.10.5305] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
We identified two novel isoforms of the human chemokine receptor CX3CR1, produced by alternative splicing and with N-terminal regions extended by 7 and 32 aa. Expression of the messengers coding these isoforms, compared with that of previously described V28 messengers, is lower in monocytes and NK cells, but higher in CD4(+) T lymphocytes. CX3CR1 and its extended isoforms were expressed in HEK-293 cells and compared for expression, ligand binding, and cellular responses. In steady state experiments, all three CX3CR1 isoforms bound CX3CL1 with similar affinity. In kinetic binding studies, however, k(on) and k(off) were significantly greater for the extended CX3CR1 isoforms, thereby suggesting that the N-terminal extensions may alter the functions induced by CX3CL1. In signaling studies, all three CX3CR1 isoforms mediated agonist-dependent calcium mobilization, but the EC(50) was lower for the extended than for the standard isoforms. In addition, chemotactic responses for these extended isoforms shifted left, also indicating a more sensitive response. Finally, the longer variants appeared to be more potent HIV coreceptors when tested in fusion and infection assays. In conclusion, we identified and characterized functionally two novel isoforms of CX3CR1 that respond more sensitively to CX3CL1 and HIV viral envelopes. These data reveal new complexity in CX3CR1 cell activation and confirm the critical role of the N-terminal domain of the chemokine receptors in ligand recognition and cellular response.
Collapse
MESH Headings
- Alternative Splicing/immunology
- Amino Acid Sequence
- Base Sequence
- CX3C Chemokine Receptor 1
- Cell Line
- Cells, Cultured
- Chemokine CX3CL1
- Chemokine CXCL1
- Chemokines, CX3C/biosynthesis
- Chemokines, CX3C/genetics
- Chemokines, CX3C/isolation & purification
- Chemokines, CX3C/metabolism
- Chemokines, CXC/agonists
- Chemokines, CXC/metabolism
- Chemotaxis, Leukocyte/genetics
- Chemotaxis, Leukocyte/immunology
- Gene Expression Regulation/immunology
- Humans
- Intercellular Signaling Peptides and Proteins/agonists
- Intercellular Signaling Peptides and Proteins/metabolism
- Membrane Proteins/biosynthesis
- Membrane Proteins/genetics
- Membrane Proteins/isolation & purification
- Membrane Proteins/metabolism
- Molecular Sequence Data
- Protein Binding/genetics
- Protein Binding/immunology
- Protein Isoforms/biosynthesis
- Protein Isoforms/genetics
- Protein Isoforms/isolation & purification
- Protein Isoforms/metabolism
- RNA, Messenger/biosynthesis
- Receptors, Chemokine/agonists
- Receptors, Chemokine/biosynthesis
- Receptors, Chemokine/genetics
- Receptors, Chemokine/metabolism
- Receptors, HIV/physiology
- Transfection
Collapse
Affiliation(s)
- Alexandre Garin
- Laboratoire d'Immunologie Cellulaire et Tissulaire, Institut National de la Santé et de la Recherche Médicale, Unité 543, Hôpital Pitié-Salpêtriere, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Ollivier V, Faure S, Tarantino N, Chollet-Martin S, Deterre P, Combadière C, de Prost D. Fractalkine/CX3CL1 production by human aortic smooth muscle cells impairs monocyte procoagulant and inflammatory responses. Cytokine 2003; 21:303-11. [PMID: 12824004 DOI: 10.1016/s1043-4666(03)00112-1] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Expression of membrane-bound CX3CL1, a CX(3)C chemokine, can be strongly induced by inflammatory cytokines in primary endothelial cells, mediating capture and tight adhesion of cells, such as monocytes, that carry the CX(3)CR1 receptor. Here, we measured CX3CL1 mRNA and protein induction by human aortic smooth muscle cells (SMCs), another major component of vessel walls, in response to inflammatory stimuli, and analyzed the effect of membrane-bound CX3CL1 on monocyte adhesion, tissue factor (TF) expression, and tumor necrosis factor-alpha (TNF-alpha) released. In human vascular SMCs, CX3CL1 transcripts were induced after 4h of stimulation with a combination of TNF-alpha and interferon-gamma. Cell-associated and shedded CX3CL1 were measured with a specific ELISA, showing that only 30% of the protein was cleaved from the membrane. Expression of CX3CL1 by SMC increased adhesion of monocytic cells, an effect, which was blocked by soluble CX3CL1. Interestingly, monocyte adhesion to CX3CL1-coated plates partially inhibited lipopolysaccharide-induced TF expression and TNF-alpha release. Thus, CX3CL1, in addition to its adhesive/chemotactic functions, directly promotes monocyte antiinflammatory and antiprocoagulant responses. This could have important implications in clinical settings such as atherosclerosis, in which SMCs and monocytic cells are in close proximity.
Collapse
|
26
|
Garin A, Pellet P, Deterre P, Debré P, Combadière C. Cloning and functional characterization of the human fractalkine receptor promoter regions. Biochem J 2002; 368:753-60. [PMID: 12234253 PMCID: PMC1223041 DOI: 10.1042/bj20020951] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2002] [Revised: 08/27/2002] [Accepted: 09/16/2002] [Indexed: 11/17/2022]
Abstract
We have previously shown that reduced expression of the fractalkine receptor, CX3CR1, is correlated with rapid HIV disease progression and with reduced susceptibility to acute coronary events. In order to elucidate the mechanisms underlying transcriptional regulation of CX3CR1 expression, we structurally and functionally characterized the CX3CR1 gene. It consists of four exons and three introns spanning over 18 kb. Three transcripts are produced by splicing the three untranslated exons with exon 4, which contains the complete open reading frame. The transcript predominantly found in leucocytes corresponds to the splicing of exon 2 with exon 4. Transcripts corresponding to splicing of exons 1 and 4 are less abundant in leucocytes and splicing of exons 3 and 4 are rare longer transcripts. A constitutive promoter activity was found in the regions extending upstream from untranslated exons 1 and 2. Interestingly, exons 1 and 2 enhanced the activity of their respective promoters in a cell-specific manner. These data show that the CX3CR1 gene is controlled by three distinct promoter regions, which are regulated by their respective untranslated exons and that lead to the transcription of three mature messengers. This highly complex regulation may allow versatile and precise expression of CX3CR1 in various cell types.
Collapse
MESH Headings
- Alternative Splicing
- Base Sequence
- CX3C Chemokine Receptor 1
- Cell Line
- Cells, Cultured
- Cloning, Molecular
- DNA, Complementary/metabolism
- Exons
- Gene Deletion
- Gene Expression Regulation
- HL-60 Cells
- HeLa Cells
- Humans
- Molecular Sequence Data
- Open Reading Frames
- Plasmids/metabolism
- Promoter Regions, Genetic
- RNA, Messenger/metabolism
- Receptors, Cytokine/chemistry
- Receptors, Cytokine/genetics
- Receptors, HIV/chemistry
- Receptors, HIV/genetics
- Reverse Transcriptase Polymerase Chain Reaction
- Transcription, Genetic
Collapse
Affiliation(s)
- Alexandre Garin
- Laboratoire d'Immunologie Cellulaire et Tissulaire, INSERM U543, Hôpital Pitié-Salpêtrière, 91 Boulevard de l'Hôpital, AP-HP, 75634 Paris cedex 13, France
| | | | | | | | | |
Collapse
|
27
|
Affiliation(s)
- P Deterre
- Laboratoire d'Immunologie Cellulaire UMR CNRS 7627, Hôpital Pitié-Salpêtrière, Paris.
| | | | | | | | | | | |
Collapse
|
28
|
Abstract
The lymphoid surface antigen CD38 is basically a NAD+glycohydrolase, which is also involved in the metabolism of cyclic ADP-ribose. Besides, this ecto-enzyme has potential signalling roles in T- and B-cells. Such multiple functions prompted us to study the molecular dynamics of the CD38 protein and especially the relationship between its ecto-enzymatic active site and its epitope, i.e. the binding site of most known anti-CD38 monoclonal antibodies. Both epitopic and enzymatic sites were shown to be degraded by proteases, such as trypsin or chymotrypsin. This sensitivity was almost entirely suppressed in the presence of substrates or inhibitors. Both sites were also degraded in the presence of reducing agents, as dithiothreitol. Inhibitory ligands induced the same resistance of both sites against reducing attack. The binding of CD38 ligands to the active site triggers therefore conformational changes that shield some backbone bonds and disulfide bridges against, respectively, proteolytic cleavage or reduction. This transconformation was found moreover to irreversibly take place after incubation with substrates such as NAD+ in the presence of dithiothreitol. The epitope remained preserved, while the enzymatic activity was lost. This inactivation probably resulted from the covalent trapping of the catalytically reactive intermediate in the active site (i.e. paracatalytic inactivation). These data have major implications in the knowledge of the CD38 structure, especially with regard to the location of disulfide bridges and their accessibility. Potential consequences of the conformational plasticity of CD38 should also be considered in its physiological functions such as signalling.
Collapse
Affiliation(s)
- V Berthelier
- Laboratoire d'Immunologie Cellulaire, UMR 7627 CNRS, Hôpital Pitié-Salpétrière, Paris, France
| | | | | | | | | |
Collapse
|
29
|
Bauvois B, Durant L, Laboureau J, Barthélémy E, Rouillard D, Boulla G, Deterre P. Upregulation of CD38 gene expression in leukemic B cells by interferon types I and II. J Interferon Cytokine Res 1999; 19:1059-66. [PMID: 10505750 DOI: 10.1089/107999099313299] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The activation antigen CD38, which has NAD+ glycohydrolase activity in its extracellular domain, is expressed by a large variety of cell types. Few investigations into the regulation of CD38 expression by physiologic stimuli have been reported. As the CD38 promoter contains potential binding sites for interferon (IFN) regulatory factor-1 (IRF-1), we investigated the influence of IFN type I (alpha and beta) and type II (gamma) on CD38 gene expression of leukemic B cells. Using the IFN-responsive B cell line Eskol, we found by RT-PCR analysis a rapid time-dependent induction in CD38 mRNA (starting at 6 h) with each type of IFN. This induction was independent of protein synthesis, suggesting that CD38 gene activation does not require IRF-1 but is merely under direct transcriptional regulation by latent IFN-inducible factors. mRNA stimulation was followed within 24 h by induction of membrane CD38, which coincided with rises of CD38-specific ectoenzymatic activities, that is, NAD+ glycohydrolase, (A/G)DP-ribosyl cyclase, and cyclic ADP ribose hydrolase activities. IFN failed to induce or upregulate the other CD38-related ectoenzymes analyzed, that is, CD39, CD73, CD157, and PC-1. Similarly, treatment of leukemic cells of patients with B chronic lymphocytic leukemia (B-CLL) with IFN resulted in an increase in CD38 mRNA mirrored by plasma membrane upregulation of CD38 and NAD+ glycohydrolase activity. Further investigation in relation to CD38 gene activation and B-CLL behavior remains to be defined.
Collapse
Affiliation(s)
- B Bauvois
- Unité 365 INSERM, Institut Curie, Paris, France.
| | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
The leucoyte surface antigen CD38 has been shown to be an ecto-enzyme with multiple catalytic activities. It is principally a NAD+ glycohydrolase that transforms NAD+ into ADP-ribose and nicotinamide. CD38 is also able to produce small amounts of cyclic ADP-ribose (ADP-ribosyl cyclase activity) and to hydrolyse this cyclic metabolite into ADP-ribose (cyclic ADP-ribose hydrolase activity). To classify CD38 among the enzymes that transfer the ADP-ribosyl moiety of NAD+ to a variety of acceptors, we have investigated its substrate specificity and some characteristics of its kinetic and molecular mechanisms. We find that CD38-catalysed cleavage of the nicotinamide-ribose bond results in the formation of an E.ADP-ribosyl intermediary complex, which is common to all reaction pathways; this intermediate reacts (1) with acceptors such as water (hydrolysis), methanol (methanolysis) or pyridine (transglycosidation), and (2) intramolecularly, yielding cyclic ADP-ribose with a low efficiency. This reaction scheme is also followed when using nicotinamide guanine dinucleotide as an alternative substrate; in this case, however, the cyclization process is highly favoured. The results obtained here are not compatible with the prevailing model for the mode of action of CD38, according to which this enzyme produces first cyclic ADP-ribose which is then immediately hydrolysed into ADP-ribose (i.e. sequential ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities). We show instead that the cyclic metabolite was a reaction product of CD38 rather than an obligatory reaction intermediate during the glycohydrolase activity. Altogether our results lead to the conclusion that CD38 is an authentic 'classical' NAD(P)+ glycohydrolase (EC 3.2.2.6).
Collapse
Affiliation(s)
- V Berthelier
- Laboratoire d'Immunologie Cellulaire, Unité Associée 625 du Centre National de la Recherche Scientifique, Groupe Hospitalier Pitié-Salpêtière, 83 boulevard de l'Hôpital, 75013 Paris, France
| | | | | | | | | |
Collapse
|
31
|
Goding JW, Terkeltaub R, Maurice M, Deterre P, Sali A, Belli SI. Ecto-phosphodiesterase/pyrophosphatase of lymphocytes and non-lymphoid cells: structure and function of the PC-1 family. Immunol Rev 1998; 161:11-26. [PMID: 9553761 DOI: 10.1111/j.1600-065x.1998.tb01568.x] [Citation(s) in RCA: 124] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Many developmentally regulated membrane proteins of lymphocytes are ecto-enzymes, with their active sites on the external surface of the cell. These enzymes commonly have peptidase, phosphodiesterase or nucleotidase activity. Their biological roles are just beginning to be discovered. Although their expression is usually associated with particular stages of lymphoid differentiation, the same gene products are often expressed on the surface of certain non-lymphoid cell types outside the immune system, indicating that their functions cannot be unique to lymphocytes, nor can they be ubiquitous. The plasma cell membrane protein PC-1 (phosphodiesterase I; EC 3.1.4.1/nucleotide pyrophosphatase; EC 3.6.1.9), which was one of the first serological markers for lymphocyte subsets to be discovered, is a typical example. Within the immune system, PC-1 is confined to plasma cells, which represent about 0.1% of lymphocytes. However, PC-1 is also expressed on cells of the distal convoluted tubule of the kidney, chondrocytes, osteoblasts, epididymis and hepatocytes. Recent work has shown that PC-1 is a member of a multigene family of ecto-phosphodiesterases that currently has two other members, PD-1 alpha (autotaxin) and PD-1 beta (B10). Within this family, the extracellular domains are highly conserved, especially around the active site. In contrast, the transmembrane and cytoplasmic domains are highly divergent. Individual members of the eco-phosphodiesterase family have distinct patterns of distribution in different cell types, and even within the same cell. For example, PC-1 is present only on the basolateral surface of hepatocytes, while B10 (PD-1 beta) is confined to the apical surface. Analysis of conservation and differences in the sequence of their cytoplasmic tails may illuminate intracellular targetting signals. Ecto-phosphodiesterases may play a part in diverse activities in different tissues, including recycling of nucleotides. They may also regulate the concentration of pharmacologically active extracellular compounds such as adenosine or its derivatives and cell motility. Some members may modulate local concentrations of pyrophosphate, and hence influence calcification in bone and cartilage.
Collapse
Affiliation(s)
- J W Goding
- Department of Pathology and Immunology, Monash Medical School, Alfred Hospital, Prahran, Victoria, Australia.
| | | | | | | | | | | |
Collapse
|
32
|
Deterre P, Gelman L, Gary-Gouy H, Arrieumerlou C, Berthelier V, Tixier JM, Ktorza S, Goding J, Schmitt C, Bismuth G. Coordinated regulation in human T cells of nucleotide-hydrolyzing ecto-enzymatic activities, including CD38 and PC-1. Possible role in the recycling of nicotinamide adenine dinucleotide metabolites. J Immunol 1996; 157:1381-8. [PMID: 8759717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The human leukocyte surface Ag CD38 was recently identified as a nicotinamide adenine dinucleotide (NAD)(+)-glycohydrolase ecto-enzyme, degrading NAD into nicotinamide and ADP-ribose. We show here that expression of CD38 is increased in the Jurkat T cell line after treatment with agents that augment intracellular cAMP, with the permeant cAMP analogue dibutyryl-cAMP (db-cAMP), and also with PMA, which activates protein kinase C. Treatment of human PBL T cells with db-cAMP or submitogenic doses of PMA also increased CD38 expression. Two other nucleotide-hydrolyzing activities were induced on the T cell surface concomitantly with CD38: the human PC-1 molecule, a nucleotide phosphodiesterase/pyrophosphatase that produces AMP from NAD or ADP-ribose, and a nucleotidase that produces adenosine from AMP, but which may be distinct from the CD73 5'-nucleotidase. All three enzymes were up-regulated after stimulation of human peripheral blood T cells with PHA. The coordinated regulation of these ecto-enzymes suggested that, besides a possible signaling function, they may recycle extracellular NAD by degrading it to adenosine and nicotinamide, which can be taken up by cells. In support of this hypothesis, db-cAMP-treated Jurkat cells could degrade extracellular NAD for de novo synthesis of purines, while untreated cells could not. Activated lymphocytes are often located in tissues in which cell death is common. It is suggested that the coordinated expression of these enzymes may allow activated T cells to re-use NAD and nucleotides from dead cells.
Collapse
Affiliation(s)
- P Deterre
- Laboratory of Cellular Immunology, Hospital Pitié-Salpêtrière Group, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Deterre P, Gelman L, Gary-Gouy H, Arrieumerlou C, Berthelier V, Tixier JM, Ktorza S, Goding J, Schmitt C, Bismuth G. Coordinated regulation in human T cells of nucleotide-hydrolyzing ecto-enzymatic activities, including CD38 and PC-1. Possible role in the recycling of nicotinamide adenine dinucleotide metabolites. The Journal of Immunology 1996. [DOI: 10.4049/jimmunol.157.4.1381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Abstract
The human leukocyte surface Ag CD38 was recently identified as a nicotinamide adenine dinucleotide (NAD)(+)-glycohydrolase ecto-enzyme, degrading NAD into nicotinamide and ADP-ribose. We show here that expression of CD38 is increased in the Jurkat T cell line after treatment with agents that augment intracellular cAMP, with the permeant cAMP analogue dibutyryl-cAMP (db-cAMP), and also with PMA, which activates protein kinase C. Treatment of human PBL T cells with db-cAMP or submitogenic doses of PMA also increased CD38 expression. Two other nucleotide-hydrolyzing activities were induced on the T cell surface concomitantly with CD38: the human PC-1 molecule, a nucleotide phosphodiesterase/pyrophosphatase that produces AMP from NAD or ADP-ribose, and a nucleotidase that produces adenosine from AMP, but which may be distinct from the CD73 5'-nucleotidase. All three enzymes were up-regulated after stimulation of human peripheral blood T cells with PHA. The coordinated regulation of these ecto-enzymes suggested that, besides a possible signaling function, they may recycle extracellular NAD by degrading it to adenosine and nicotinamide, which can be taken up by cells. In support of this hypothesis, db-cAMP-treated Jurkat cells could degrade extracellular NAD for de novo synthesis of purines, while untreated cells could not. Activated lymphocytes are often located in tissues in which cell death is common. It is suggested that the coordinated expression of these enzymes may allow activated T cells to re-use NAD and nucleotides from dead cells.
Collapse
Affiliation(s)
- P Deterre
- Laboratory of Cellular Immunology, Hospital Pitié-Salpêtrière Group, Paris, France
| | - L Gelman
- Laboratory of Cellular Immunology, Hospital Pitié-Salpêtrière Group, Paris, France
| | - H Gary-Gouy
- Laboratory of Cellular Immunology, Hospital Pitié-Salpêtrière Group, Paris, France
| | - C Arrieumerlou
- Laboratory of Cellular Immunology, Hospital Pitié-Salpêtrière Group, Paris, France
| | - V Berthelier
- Laboratory of Cellular Immunology, Hospital Pitié-Salpêtrière Group, Paris, France
| | - J M Tixier
- Laboratory of Cellular Immunology, Hospital Pitié-Salpêtrière Group, Paris, France
| | - S Ktorza
- Laboratory of Cellular Immunology, Hospital Pitié-Salpêtrière Group, Paris, France
| | - J Goding
- Laboratory of Cellular Immunology, Hospital Pitié-Salpêtrière Group, Paris, France
| | - C Schmitt
- Laboratory of Cellular Immunology, Hospital Pitié-Salpêtrière Group, Paris, France
| | - G Bismuth
- Laboratory of Cellular Immunology, Hospital Pitié-Salpêtrière Group, Paris, France
| |
Collapse
|
34
|
Affiliation(s)
- V Berthelier
- Laboratoire d'Immunologie Cellulaire, URA CNRS 625, Groupe Hospitalier Pitié-Salpêtrière, Paris
| | | | | | | | | |
Collapse
|
35
|
Bruckert F, Catty P, Deterre P, Pfister C. Activation of phosphodiesterase by transducin in bovine rod outer segments: characteristics of the successive binding of two transducins. Biochemistry 1994; 33:12625-34. [PMID: 7918488 DOI: 10.1021/bi00208a013] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
In bovine retinal rods, transducin loaded with GTP or GTP gamma S (T*) activates a cGMP phosphodiesterase (PDE) by forming a tightly membrane-bound complex with it [Catty, P., et al. (1992) J. Biol. Chem. 267, 19489-19493]. Up to two T*s are able to bind to PDE [Clerc, A., & Bennett, N. (1992) J. Biol. Chem. 267, 6620-6627]. We analyze here PDE activation by two successive bindings of T*. In the mathematical model used, we took into account that the membrane concentration determines the amount of PDE able to interact efficiently with T* through the attachment of PDE itself to the membrane. We therefore fitted the data obtained over a wide range of membrane and PDE concentrations. We found that the binding of the first T* to PDE elicits 80-100% of the maximal activity of PDE, whereas the binding of the second T* to PDE elicits little or no additional activation of PDE. This finding profoundly differs from previous conclusions. The carefully controlled conditions of our experiments permit one to understand these discrepancies. In the physiological situation, PDE would be nearly maximally activated through its interaction with only one T*. The efficient binding of the second T* to those complexes would then ensure a rapid deactivation of T* through the enhancement of the rate of GTP hydrolysis in T* bound to PDE [Pagès, F., et al. (1992) J. Biol. Chem. 267, 22018-22021; Pagès, F., et al. (1993) J. Biol. Chem. 268, 26358-26364].
Collapse
Affiliation(s)
- F Bruckert
- Département de Biologie Moléculaire et Structurale, Centre d'Etudes Nucléaires, Grenoble, France
| | | | | | | |
Collapse
|
36
|
Gouy H, Deterre P, Debré P, Bismuth G. Cell calcium signaling via GM1 cell surface gangliosides in the human Jurkat T cell line. The Journal of Immunology 1994. [DOI: 10.4049/jimmunol.152.7.3271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Abstract
The cell surface ganglioside GM1 is the specific receptor for the B subunit of cholera toxin. We show here that in the human Jurkat T cell line an increase in intracellular free Ca2+ concentration can be elicited by using B subunits to ligate GM1 molecules. This Ca2+ signaling effect is clearly mediated through GM1 because it can be observed after direct insertion of exogenous GM1 in a Jurkat cell variant deficient in GM1 expression. The observed Ca2+ response clearly involves both the release of Ca2+ from intracellular stores and a Ca2+ influx from extracellular spaces. It is sustained in the presence of 1 mM extracellular Ca2+, whereas it becomes transient in Ca(2+)-free medium. We show that the GM1-mediated stimulation partially empties the CD3-dependent and inositol 1,4,5-trisphosphate-sensitive intracellular Ca2+ pool suggesting a dependence of the Ca2+ response from activation of phospholipase C (PLC) metabolism. Accordingly, tyrosine phosphorylation of PLC gamma-1 can be evidenced but only in Jurkat cells highly expressing GM1. GM1 stimulation results in an IL-2 production comparable to that obtained after CD3 activation. Finally, the GM1-linked cell Ca2+ activation pathway is also observed in a Jurkat cell clone lacking Ag-specific receptor expression suggesting that the presence of functional CD3/TCR molecules is not essential for GM1-induced cell Ca2+ response. Altogether, these data show that cell surface gangliosides GM1 may act as a signaling molecule in Jurkat T cells possibly by a new pathway, a finding of importance when considering a possible function for ubiquitous membrane carbohydrate structures in T cell recognition systems.
Collapse
Affiliation(s)
- H Gouy
- Laboratoire d'Immunologie Cellulaire et Tissulaire, CNRS URA 625, CERVI, Hôpital Pitié-Salpétrière, Paris, France
| | - P Deterre
- Laboratoire d'Immunologie Cellulaire et Tissulaire, CNRS URA 625, CERVI, Hôpital Pitié-Salpétrière, Paris, France
| | - P Debré
- Laboratoire d'Immunologie Cellulaire et Tissulaire, CNRS URA 625, CERVI, Hôpital Pitié-Salpétrière, Paris, France
| | - G Bismuth
- Laboratoire d'Immunologie Cellulaire et Tissulaire, CNRS URA 625, CERVI, Hôpital Pitié-Salpétrière, Paris, France
| |
Collapse
|
37
|
Gouy H, Deterre P, Debré P, Bismuth G. Cell calcium signaling via GM1 cell surface gangliosides in the human Jurkat T cell line. J Immunol 1994; 152:3271-81. [PMID: 7511641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The cell surface ganglioside GM1 is the specific receptor for the B subunit of cholera toxin. We show here that in the human Jurkat T cell line an increase in intracellular free Ca2+ concentration can be elicited by using B subunits to ligate GM1 molecules. This Ca2+ signaling effect is clearly mediated through GM1 because it can be observed after direct insertion of exogenous GM1 in a Jurkat cell variant deficient in GM1 expression. The observed Ca2+ response clearly involves both the release of Ca2+ from intracellular stores and a Ca2+ influx from extracellular spaces. It is sustained in the presence of 1 mM extracellular Ca2+, whereas it becomes transient in Ca(2+)-free medium. We show that the GM1-mediated stimulation partially empties the CD3-dependent and inositol 1,4,5-trisphosphate-sensitive intracellular Ca2+ pool suggesting a dependence of the Ca2+ response from activation of phospholipase C (PLC) metabolism. Accordingly, tyrosine phosphorylation of PLC gamma-1 can be evidenced but only in Jurkat cells highly expressing GM1. GM1 stimulation results in an IL-2 production comparable to that obtained after CD3 activation. Finally, the GM1-linked cell Ca2+ activation pathway is also observed in a Jurkat cell clone lacking Ag-specific receptor expression suggesting that the presence of functional CD3/TCR molecules is not essential for GM1-induced cell Ca2+ response. Altogether, these data show that cell surface gangliosides GM1 may act as a signaling molecule in Jurkat T cells possibly by a new pathway, a finding of importance when considering a possible function for ubiquitous membrane carbohydrate structures in T cell recognition systems.
Collapse
Affiliation(s)
- H Gouy
- Laboratoire d'Immunologie Cellulaire et Tissulaire, CNRS URA 625, CERVI, Hôpital Pitié-Salpétrière, Paris, France
| | | | | | | |
Collapse
|
38
|
Deterre P. De la recherche scientifique et de la foi chrétienne. Med Sci (Paris) 1994. [DOI: 10.4267/10608/2689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
39
|
Pagès F, Deterre P, Pfister C. Enhancement by phosphodiesterase subunits of the rate of GTP hydrolysis by transducin in bovine retinal rods. Essential role of the phosphodiesterase catalytic core. J Biol Chem 1993; 268:26358-64. [PMID: 8253760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Phosphodiesterase (PDE) in bovine retinal rod outer segments is activated when it forms a membrane-bound complex with the alpha-subunit of transducin loaded with GTP (T alpha*). At maximal activation, this complex contains two T alpha* and all the subunits of native PDE (PDE alpha, PDE beta, and two inhibitory PDE gamma). We observed previously (Pagès, F., Deterre, P., and Pfister, C. (1992) J. Biol. Chem. 267, 22018-22021) that the rate of GTP hydrolysis by transducin in a rod outer segment suspension is enhanced when T alpha* is bound to native PDE (PDE alpha beta gamma 2). In this article, we compare the effects of PDE species with different PDE gamma contents. We show that T alpha* hydrolyzes its GTP faster not only when bound to PDE alpha beta gamma 2, but also when bound to PDE alpha beta gamma or PDE alpha beta. Moreover, trypsin-treated PDE (PDE gamma-deprived soluble PDE) also induces an acceleration of GTP hydrolysis. On the contrary, addition of isolated PDE gamma alone does not accelerate GTP hydrolysis. The interaction between T alpha* and PDE gamma, which is essential for the activation of PDE by T alpha*, is apparently not responsible of the feedback of PDE on T alpha*. The interaction of primary importance for the acceleration of GTP hydrolysis would be that existing between T alpha* and PDE alpha beta.
Collapse
Affiliation(s)
- F Pagès
- Département de Biologie Moléculaire et Structurale, Centre d'Etudes Nucléaires de Grenoble, France
| | | | | |
Collapse
|
40
|
Gelman L, Deterre P, Gouy H, Boumsell L, Debré P, Bismuth G. The lymphocyte surface antigen CD38 acts as a nicotinamide adenine dinucleotide glycohydrolase in human T lymphocytes. Eur J Immunol 1993; 23:3361-4. [PMID: 8258350 DOI: 10.1002/eji.1830231245] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The extracellular domain of the lymphocyte surface antigen CD38 has been recently shown to share a high sequence homology with a nicotinamide adenine dinucleotide (NAD+)-specific hydrolyzing enzyme cloned from the ovotestis of the gastropod Aplysia (E. States, D.J., Walseth, T.F., Lee, H. C., Trends Biochem. Sci. 1992. 17:495). In agreement with this finding, we present here evidence that CD38-overexpressing T cells, such as human thymocytes and cells from the human HPB-ALL T cell line, exhibit a NAD(+)-hydrolyzing enzymatic activity present on the outer surface of the cell membrane. In contrast, T lymphocytes with relatively low levels of CD38 marker, such as the human Jurkat cell line, display a lower activity. This suggests a relationship between ecto-NAD+ glycohydrolase activity and CD38 expression, as confirmed here when comparing wild-type Jurkat cells and a Jurkat cell variant overexpressing the CD38 molecule. Moreover, CD38 immunoprecipitates from thymocytes behave as an authentic NAD+ glycohydrolase enzyme: it transforms NAD+ stoichiometrically into nicotinamide plus adenosine 5'-diphosphoribose. Altogether these results strongly support the assumption that CD38 is actually a lymphocyte-specific NAD(+)-hydrolyzing enzyme, a finding that give new prospects to understand the in vivo function of this cell membrane protein.
Collapse
Affiliation(s)
- L Gelman
- Laboratoire d'Immunologie Cellulaire et Tissulaire, CNRS URA 625, Groupe Hospitalier Pitié-Salpétrière, Paris, France
| | | | | | | | | | | |
Collapse
|
41
|
Pfister C, Bennett N, Bruckert F, Catty P, Clerc A, Pagès F, Deterre P. Interactions of a G-protein with its effector: transducin and cGMP phosphodiesterase in retinal rods. Cell Signal 1993; 5:235-41. [PMID: 7688544 DOI: 10.1016/0898-6568(93)90015-e] [Citation(s) in RCA: 72] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- C Pfister
- Laboratoire de Biophysique Moléculaire et Cellulaire, Unité Associée 520 du Centre National de la Recherche Scientifique, Centre d'Etudes Nucléaires, Grenoble, France
| | | | | | | | | | | | | |
Collapse
|
42
|
Pagès F, Deterre P, Pfister C. Enhanced GTPase activity of transducin when bound to cGMP phosphodiesterase in bovine retinal rods. J Biol Chem 1992; 267:22018-21. [PMID: 1331045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
The generation of the physiological response of a retinal rod cell to an incident photon involves activation of a cGMP phosphodiesterase (PDE) by a GTP-binding protein, transducin (T). This activation has been shown to occur by formation of a membrane-bound T alpha GTP-PDE complex (Clerc, A., and Bennett, N. (1992) J. Biol. Chem. 267, 6620-6627; Catty, P., Pfister, C., Bruckert, F., and Deterre, P. (1992) J. Biol. Chem 267, 19489-19493). The recovery of the response involves turning-off of T by its intrinsic GTPase activity. We show here that the formation of the membrane-bound T alpha GTP-PDE complex correlates with an enhanced rate of GTP hydrolysis. In vivo, this would provide an appropriate mechanism for fast turn-off of cGMP hydrolysis.
Collapse
Affiliation(s)
- F Pagès
- Département de Biologie Moléculaire et Structurale, Centre d'Etudes Nucléaires de Grenoble, France
| | | | | |
Collapse
|
43
|
Catty P, Pfister C, Bruckert F, Deterre P. The cGMP phosphodiesterase-transducin complex of retinal rods. Membrane binding and subunits interactions. J Biol Chem 1992; 267:19489-93. [PMID: 1326553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
cGMP-specific phosphodiesterase (PDE) of vertebrate retinal rod outer segments (ROS) is composed of two catalytic subunits (PDE alpha and PDE beta) and two identical inhibitory subunits (PDE gamma). Native PDE alpha beta gamma 2 is peripherally bound to the membranes of ROS discs. We studied quantitatively its partition between soluble and membrane-bound fractions in ROS homogenates. In the presence of its activator, the alpha-subunit of transducin loaded with a triphosphate guanine nucleotide (T alpha*), PDE displayed a greatly enhanced membrane binding. Neither the purified PDE gamma.T alpha* complex, nor the PDE alpha beta and PDE alpha beta gamma forms of active PDE, showed a membrane binding comparable to that of PDE alpha beta gamma 2 in the presence of T alpha*. The T alpha*-activated PDE is therefore an undissociated complex tightly bound to the ROS membranes. Using limited proteolysis, we showed that the membrane anchoring of the whole complex implies not only PDE (mainly by the C terminus of PDE beta) but also both termini of T alpha*. The membrane binding of the purified PDE alpha beta species was also enhanced in the presence of T alpha*; a direct link would therefore exist between the activator and the catalytic subunits. From this work emerges a plausible structural model of the T alpha*-activated PDE, with its internal interactions and its sites of anchoring into the ROS membrane.
Collapse
Affiliation(s)
- P Catty
- Laboratoire de Biophysique Moléculaire et Cellulaire, Unité Associée 520 du Centre National de la Recherche Scientifici, Centre d'Etudes Nucléaires, Grenoble, France
| | | | | | | |
Collapse
|
44
|
Catty P, Pfister C, Bruckert F, Deterre P. The cGMP phosphodiesterase-transducin complex of retinal rods. Membrane binding and subunits interactions. J Biol Chem 1992. [DOI: 10.1016/s0021-9258(18)41802-9] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
45
|
Lotersztajn S, Pavoine C, Deterre P, Capeau J, Mallat A, LeNguyen D, Dufour M, Rouot B, Bataille D, Pecker F. Role of G protein beta gamma subunits in the regulation of the plasma membrane Ca2+ pump. J Biol Chem 1992; 267:2375-9. [PMID: 1310315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
In Zajdela hepatoma cells (ZHC) the plasma membrane Ca2+ pump displayed no sensitivity to glucagon (19-29) (mini-glucagon), whereas in hepatocyte this metabolite of glucagon evoked a biphasic regulation of the Ca2+ pump system via a cholera toxin-sensitive G protein. Analysis of G protein subunits in ZHC membranes indicated the presence of cholera toxin-sensitive Gs alpha and G beta gamma proteins, whose functionality was manifested by GTP and NaF stimulation of adenylylcyclase activity, and pertussis toxin-catalyzed ADP-ribosylation of Gi alpha, respectively. However, immunoblotting experiments suggested a lower content in beta gamma subunits in ZHC as compared with hepatocyte plasma membranes. Complementation of ZHC or hepatocyte plasma membranes with purified beta gamma subunits from transducin (T beta gamma) caused inhibition of the basal activity of the Ca2+ pump at 10 and 300 ng/ml, respectively, and revealed (in ZHC) or increased (in hepatocytes) sensitivity of the system to mini-glucagon. After cholera toxin treatment of ZHC, T beta gamma no longer reconstituted the response of the Ca2+ pump to mini-glucagon, suggesting that the mechanism of beta gamma action is dependent on an association with the alpha subunit of a cholera toxin-sensitive G protein. It is concluded that G beta gamma subunits control both the basal activity of the plasma membrane Ca2+ pump and its inhibition by mini-glucagon.
Collapse
Affiliation(s)
- S Lotersztajn
- Institut National de la Santé et la Recherche Médicale Unité 99, Hôpital Henri Mondor, Créteil, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Lotersztajn S, Pavoine C, Deterre P, Capeau J, Mallat A, LeNguyen D, Dufour M, Rouot B, Bataille D, Pecker F. Role of G protein beta gamma subunits in the regulation of the plasma membrane Ca2+ pump. J Biol Chem 1992. [DOI: 10.1016/s0021-9258(18)45889-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
47
|
Catty P, Deterre P. Activation and solubilization of the retinal cGMP-specific phosphodiesterase by limited proteolysis. Role of the C-terminal domain of the beta-subunit. Eur J Biochem 1991; 199:263-9. [PMID: 1649045 DOI: 10.1111/j.1432-1033.1991.tb16119.x] [Citation(s) in RCA: 57] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The cGMP-specific phosphodiesterase (PDE) of vertebrate retinal rod outer segments (ROS) is a peripheral enzyme activated in vivo by transducin. In vitro artificial activation can be achieved using trypsin. This was described as resulting from degradation of the inhibitory gamma subunit (2 copies/PDE molecule), leaving intact the alpha beta catalytic core. It was, however, observed that trypsin could induce the release of PDE (or solubilization) from the ROS membranes before its activation [Wensel, T. G. & Stryer, L. (1986) Proteins Struct. Funct. Genet. 1, 90-99]. Studying the time course of this solubilization, we were able to purify a trypsin-solubilized PDE still completely inhibited (i.e. with its two gamma subunits bound). The tryptic solubilization of PDE is therefore complete before any functional degradation of the gamma subunits occurs. It was recently suggested that this solubilization could coincide with the cleavage of a C-terminal fragment of the alpha subunit, which can be labeled by methylation of a terminal cysteine residue [Ong, O. C., Ota, I. M., Clarke, S. & Fung, B. K. K. (1989) Proc. Natl Acad. Sci. USA 86, 9238-9242]. We present the following evidence indicating that the C-terminus of the PDE beta subunit is mainly responsible for PDE anchorage to the ROS membrane. (a) The trypsin-solubilized PDE alpha beta gamma 2 has intact blocked N-termini. (b) It is still methylated on PDE alpha. (c) The C-terminus of PDE beta can also be labeled by methylation and its tryptic cleavage coincides well with the PDE solubilization. (d) Sequential cleavage of the alpha and beta polypeptides can also be detected by high-resolution gel electrophoresis: the first cleavage appears on the beta subunit and is completed when cleavage of the alpha subunit begins. The time course for cleavage of the gamma subunits appears to be slower than for the beta subunit and comparable to that of the alpha subunit. Upon longer trypsinization, a 70-kDa polypeptide appears which seems to be a degradation product of PDE beta. Gel-filtration analysis, however, shows that this 70-kDa fragment does not dissociate from the catalytic core.
Collapse
Affiliation(s)
- P Catty
- Départment de Biologie Moléculaire et Structurale, Centre d'Etudes Nucléaires, Grenoble, France
| | | |
Collapse
|
48
|
Affiliation(s)
- M Chabre
- Laboratoire de Biophysique Moléculaire et Cellulaire Unité Associée 520 au CNRS), Département Recherche Fondamentale, Grenoble, France
| | | |
Collapse
|
49
|
Deterre P, Bigay J, Forquet F, Robert M, Chabre M. cGMP phosphodiesterase of retinal rods is regulated by two inhibitory subunits. Proc Natl Acad Sci U S A 1988; 85:2424-8. [PMID: 2833739 PMCID: PMC280009 DOI: 10.1073/pnas.85.8.2424] [Citation(s) in RCA: 198] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
The cGMP phosphodiesterase (PDE) of cattle retinal rod outer segments comprises three types of subunits: the two heavy catalytic ones, PDE alpha and PDE beta, each around 85 kDa, and the light inhibitory one, PDE gamma or I (11 kDa). The relative stoichiometry is usually assumed to be 1:1:1. PDE activation in the visual transduction cascade results from removal of the inhibitor by the alpha subunit of transducin (T alpha). The stoichiometric complex T alpha-I, separated from activated PDE, has been isolated and characterized. Analyzing now the activated PDE, we find that it still contains some inhibitor and is resolvable into two species, one with 50% of the inhibitor content of the native enzyme and the other totally devoid of it. The same two species are observed upon activation of PDE by very short tryptic proteolysis, which specifically degrades the inhibitor. This leads us to conclude that the composition of the native enzyme is PDE alpha beta-I2. The two inhibitory subunits are differentially bound, sequentially removable, and exchangeable between the native complex PDE alpha beta-I2 and the fully active PDE alpha beta. The possibility of this exchange precludes as yet an unambiguous estimate of the actual activity of the intermediate complex PDE alpha beta-I. The differential binding and the exchangeability of the inhibitors raises the possibility of a fast, diffusion controlled, switch-off mechanism of PDE activity after a flash, which would shortcut the inactivation resulting from the slow GTPase rate of transducin.
Collapse
Affiliation(s)
- P Deterre
- Laboratoire de Biophysique Moléculaire et Cellulaire, Unité Associée 520 du Centre National de la Recherche Scientifique, DRF/CENG, Grenoble, France
| | | | | | | | | |
Collapse
|
50
|
Chabre M, Bigay J, Bruckert F, Bornancin F, Deterre P, Pfister C, Vuong TM. Visual signal transduction: the cycle of transducin shuttling between rhodopsin and cGMP phosphodiesterase. Cold Spring Harb Symp Quant Biol 1988; 53 Pt 1:313-24. [PMID: 2855482 DOI: 10.1101/sqb.1988.053.01.038] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- M Chabre
- Biophysique Moléculaire et Cellulaire, Unité associée 520 du CNRS Fédération de Biologie, DRF/CENG, Grenoble, France
| | | | | | | | | | | | | |
Collapse
|